Viewpoints

The biosimilar balance: More options, lower costsThe fly in the ointment: CMS' current plan for HCPCS codes is a real buzz kill.
One thing we can do about the opioid epidemicIt's a modest proposal with potential for significant consequences. And all it will cost is a little more time.
Four people, a dozen pharmacy careers
Four people, a dozen pharmacy careersWho says the options are limited? Not this family.

Poll